Digital Health Decoded

• Isomorphic Labs, the DeepMind spinout, raises $2.1B Series B (May 12) — to scale its IsoDDE drug-design engine and push proprietary therapeutic programs toward Phase I. Existing big-pharma partnerships: Eli Lilly, Novartis, Johnson & Johnson.

  👉 Why it matters: “AI-native pharma R&D” is being treated as critical infrastructure. Sovereign wealth funds (UAE, Singapore, UK) writing checks alongside Alphabet is the signal — this is the AI drug-design layer being capitalized as a strategic asset, not a venture bet.  Bloomberg →

• Garmin CIRQA expected to launch — another screenless smart band priced around $500 with no subscription requirement (see Whoop and Fitbit Air / Google Health, Issue 5–6).

  👉 Why it matters: A growing number of screenless wearables (Whoop, Fitbit Air, Oura, Garmin CIRQA, Polar Loop, Amazfit Helio Strap) employ different business models — subscription-only vs. one-time cost. The hardware is converging while the monetization model is the differentiator.  Forbes →

• OpenEvidence hands-free Voice Mode lands Cedars-Sinai enterprise deal (May 20) — Cedars-Sinai is the third major health system (after Sutter Health in February and Mount Sinai in March) to deploy Epic-integrated OpenEvidence, the most widely used medical AI and clinical decision-making tool among U.S. physicians.

  👉 Why it matters: This is what “agentic clinical AI at scale” looks like — ~860,000 clinicians on the platform. The point-of-care AI infrastructure layer is no longer theoretical.  Press release →

• CMS Electronic Prior Authorization Acceleration Initiative (May 13) — 29 early adopters, including health systems, EHR vendors, and digital health developers (Cleveland Clinic, Ochsner Health, Epic, Oracle, athenahealth, MEDITECH), joined efforts with five major payers: UnitedHealthcare, Aetna, Cigna, Humana, and Elevance.

  👉 Why it matters: Prior authorization is the single most-cited operational friction in U.S. healthcare, costing roughly $50B/year. Having Epic, Oracle, and the four largest payers at the table = a path to a solution before the January 1, 2027 federal deadline.  CMS →

• FDA approves Gilead’s Hepcludex for chronic Hepatitis Delta Virus (HDV) (May 22) — the most severe form of viral hepatitis. This is the first therapy that blocks viral entry into hepatocytes.

  👉 Why it matters: This is the 7th accelerated approval granted under the Commissioner’s National Priority Voucher (CNPV) Pilot Program.  FDA →

Two ceilings raised in 24 hours:

• 1. Datroway (datopotamab deruxtecan) approved for 1st-line metastatic TNBC (May 22) — AstraZeneca/Daiichi Sankyo’s TROP2 antibody-drug conjugate becomes the first non-chemo 1st-line option for ~70% of metastatic TNBC patients (those not eligible for PD-1/PD-L1).

  👉 Why it matters: TROP2 ADCs join HER2 ADCs (Enhertu, Issue 6) as the second major ADC class to move up the cancer-care timeline in two weeks. Same companies (AZ + Daiichi), same DXd platform, different antigens, same story: the ADC era is operational.

• 2. Retatrutide TRIUMPH-1 Phase 3 data (May 21) — Eli Lilly’s triple agonist (GLP-1 + GIP + glucagon) hit primary endpoint with 28.3% mean weight loss at 80 weeks, and 30.3% at 104 weeks in the BMI ≥35 extension cohort.

  👉 Why it matters: The obesity drug class just crossed into territory once reserved for bariatric surgery. The Lilly → Omada coaching wrap (Issue 6) suddenly makes more sense: a drug this powerful needs a behavioral OS around it.  Lilly →

Substitution is what acceleration looks like — even when the outcome is uncertain. Four established standards of care were credibly contested this week: bariatric surgery, front-line chemo, separate reference tools, and episodic measurement. The strategic question isn’t “which capability wins?” — it’s “which organizations can absorb new capability fast enough to stay competitive while the answers are being written?”